Trials / Completed
CompletedNCT00903721
Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)
Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,806 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mometasone furoate | Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg) Duration: up to 6 months |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2009-05-18
- Last updated
- 2022-02-16
Source: ClinicalTrials.gov record NCT00903721. Inclusion in this directory is not an endorsement.